InvestorsHub Logo
Post# of 253158
Next 10
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

Re: biomaven0 post# 124600

Tuesday, 08/16/2011 8:31:08 PM

Tuesday, August 16, 2011 8:31:08 PM

Post# of 253158
XNPT @ Wedbush (8/16/11)

1. Regarding sNDA for Horizant against PHN, XNPT/GSK are seeking approval of a total 1200mg/day dose (600mg BID). The gabapentin exposure for 1200mg/day total of Horizant is 40% lower than an 1800mg/day dose of oral gabapentin (it's important to stay under the exposure of oral gabapentin for purposes of a 505(b)(2) approval). The evidence of efficacy for this dose of Horizant was from a 13-week double-blind placebo controlled study before where Horizant showed a reduction from baseline pain score of negative 2.17 compared to negative 1.27 for placebo. Also, the percent of patients with 50% reduction in pain score was 36% for Horizant 1200mg/day vs. 16% for placebo. The most common AEs for this dose were comparable to placebo as well.

2. XNPT is due $10M from Astellas upon approval of Horizant in Japan. XNPT is also due mid-teen royalties on net sales.

3. Regarding 829, more buzz about being in talks with potential partners with a statement that there could be a partnership in the "near future." Later in the presentation there was discussion about the merit of partnering now or after Phase 1 results or perhaps a little later after the potential GI safety benefit compared to BIIB's drug is proven in the clinic. Without giving a firm commitment on the specific approach, it was stated that XNPT does not expect to enter Phase 3 for 829 without a partner.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.